Washington, DC 20006-5349
HELPLINE
The Meso Foundation announced today the addition of its new communications manager. Tobias Rodriguez has joined the organization and in this role he will work…
A phase 3 randomized clinical trial looking into the efficacy of combination chemotherapy with immunotherapy is now open in the United States and Australia. How…
The Mesothelioma Applied Research Foundation’s 2020 mesothelioma research grant cycle is now accepting pre-application letters of intent (LOI) until 11:59 PM ET Sunday, Nov. 1, 2020 on proposalCENTRAL.…
Today, the Mesothelioma Applied Research Foundation announced that it will fund three research projects in the field of mesothelioma for a total investment of $300,000…
A new approach of anti-PD1 immunotherapy (atezolizumab) combined with bevacizumab (an agent that blocks the growth of new blood vessels therefore limiting the supply of…
Join us next Tuesday, June 9 at 2:00 PM ET for a Meet the Mesothelioma Experts (MTME) interview with Dr. Zachary Horne on Facebook Live.…
A phase 2 immunotherapy clinical trial combining durvalumab, an immunotherapy drug, with standard treatment of Alimta (pemetrexed)/cisplatin has shown promising overall survival results. The study enrolled 55 patients and…
In 2016, the Mesothelioma Applied Research Foundation funded a grant to Antonio Giordano, MD, PhD, director and founder of the Sbarro Health Research Organization at Temple University, to investigate how silencing…
A white paper documenting presentations and discussions from the Mesothelioma Patient Registry workshop, which was convened by the Mesothelioma Applied Research Foundation in March of…
Last week, the 9th U.S. Circuit Court of Appeals delivered a ruling addressing certain issues with the Environmental Protection Agency’s (EPA) approach to assessing risk…
Get the latest information about mesothelioma, clinical trials, patient stories, community events, and much more!
